Ark looks towards profitability, but Trinam Phase III delay disappoints
This article was originally published in Scrip
Executive Summary
Ark Therapeutics plans to launch a new wound-care product to bring it closer to profitability, but analysts are disappointed by the slow progress of the pivotal Phase III study for Trinam (haemodialysis graft stenosis).